Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Enzyme Linked to Aggressive Prostate Cancer

By Labmedica International staff writers
Posted on 17 Jan 2013
Print article
The enzyme mesotrypsin, also known as protease, serine 3 (PRSS3), is specifically associated with aggressive prostate cancer risk.

Mesotrypsin appears to be an important mediator of prostate cancer progression and metastasis, and it has been suggested that inhibition of mesotrypsin activity may provide a novel modality for prostate cancer treatment.

Cancer biologists at the Mayo Clinic (Jacksonville, Florida, USA) explored whether any other cancer abnormally expresses the enzyme PRSS3 and when this occurred. They gathered and analyzed data from several sources. They used various techniques including cell culture, ribonucleic acid (RNA) extraction and polymerase chain reaction (PCR), bioluminescent imaging, and immunohistochemistry.

By transcriptional profiling, the investigators identified a correlation between PRSS3 gene expression and prostate cancer progression in a microarray dataset in which five benign prostate, five clinically localized prostate cancer, and five metastatic prostate cancer tissue specimens. They found that PRSS3 expression in tumors was strikingly associated with recurrence, defined as systemic progression or rising prostate specific antigen. The association of PRSS3 with prostate cancer metastasis, and the evidence that PRSS3 expression in primary tumors is prognostic of recurrence, suggest that mesotrypsin may play a critical functional role in prostate cancer progression.


Evette Radisky, PhD, the senior investigator, said, "This molecule is a protease, which means it digests other molecules. Our data suggests PRSS3 activity changes the environment around prostate cancer cells, perhaps by freeing them from surrounding tissue to promote malignancy and invasiveness. I do not think PRSS3 is the only factor involved in driving aggressive prostate cancer, but it may be significant for a certain subset of this cancer, the kind that is potentially lethal. Prostate cancer patients could be tested for the presence of the enzyme, so that doctors could identify which ones had the highest risk of metastasis." The study was published on December 17, 2012, in the journal Molecular Cancer Research.

Related Links:

Mayo Clinic



Print article
Abbott Diagnostics

Channels

Lab Tech.

view channel
Image: The nano-DLD chip (2 cm x 2 cm) mounted in a microfluidic jig. The technology allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array that allows sorting a microscopic waterfall of nanoparticles, separating particles by size down to 20 nanometer resolution (Photo courtesy of IBM Research).

Lab-on-a-Chip Technology Breaks New Bioparticle Separation Record

Scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale down to 20 nanometers in diameter, a scale that gives access to important... Read more

Industry News

view channel

Critical Care Diagnostics Market Worth USD 1.29 Billion By 2024

The global critical care diagnostics (CCD) market will grow at a lucrative rate over the next few years to reach USD 1.29 billion by 2024, driven by the rapid awareness and acknowledgment of these tests by physicians and patients, rise in geriatric population and chronic health conditions, use of telehealth services in... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.